Updated Jul 16, 2026
Bisaro Paul has filed 4 SEC Form 4 filings across 3 companies in the last 90 days — buying. Lifetime open-market purchases: $179K.
Paul Bisaro is a corporate executive known for his role as a director at Myriad Genetics Inc and previously at Mallinckrodt plc. He has significant experience in the pharmaceutical and biotechnology sectors, contributing to strategic leadership and governance.
| Role | Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | MYGN | MYRIAD GENETICS INC | A — Grant or award | 59.7K | $0.00 | |
| 2026-06-04 | NONE | Mallinckrodt plc | F — Tax withholding / forfeiture | 619 | — | |
| 2026-06-04 | NONE | Mallinckrodt plc | M — Option exercise | 2.7K | — | |
| 2026-05-14 | MYGN | MYRIAD GENETICS INC | P — Open-market purchase | 7.5K | $3.69 | $28K |
| 2026-05-13 | ZTS | Zoetis Inc. | P — Open-market purchase | 2.0K | $75.88 | $152K |
| 2026-02-23 | ZTS | Zoetis Inc. | M — Option exercise | 1.6K | — | |
| 2025-06-05 | MYGN | MYRIAD GENETICS INC | A — Grant or award | 49.8K | $0.00 |
Paul Bisaro is a corporate executive known for his role as a director at Myriad Genetics Inc and previously at Mallinckrodt plc. He has significant experience in the pharmaceutical and biotechnology sectors, contributing to strategic leadership and governance.…
4 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 2 open-market purchases ($179K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Bisaro Paul profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.